Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Ends Livial Program In The U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Oraganon will drop all efforts to market its hormone therapy Livial (tibolone) in the United States following a June 1 "not approvable" letter. The company was seeking an indication for treatment of menopausal symptoms

You may also be interested in...



Pfizer Ends Asenapine Collaboration With Organon

Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.

Pfizer Ends Asenapine Collaboration With Organon

Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.

Akzo Nobel Shareholders To Vote On Organon BioSciences IPO

Dutch company’s planned separation of pharmaceuticals business from chemicals/coatings division is expected to be complete in two to three years.

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel